首页> 美国卫生研究院文献>Stem Cells International >Bone Marrow-Derived Multipotent Stromal Cells Attenuate Inflammation in Obliterative Airway Disease in Mouse Tracheal Allografts
【2h】

Bone Marrow-Derived Multipotent Stromal Cells Attenuate Inflammation in Obliterative Airway Disease in Mouse Tracheal Allografts

机译:骨髓来源的多功能基质细胞在小鼠气管同种异体移植物中消除了闭塞性气道疾病中的炎症。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Obliterative bronchiolitis (OB) remains the most significant cause of death in long-term survival of lung transplantation. Using an established murine heterotopic tracheal allograft model, the effects of different routes of administration of bone marrow-derived multipotent stromal cells (MSCs) on the development of OB were evaluated. Tracheas from BALB/c mice were implanted into the subcutaneous tissue of major histocompatibility complex- (MHC-) disparate C57BL/6 mice. At the time of transplant, bone marrow-derived MSCs were administered either systemically or locally or via a combination of the two routes. The allografts were explanted at various time points after transplantation and were evaluated for epithelial integrity, inflammatory cell infiltration, fibrosis, and luminal obliteration. We found that the most effective route of bone marrow-derived MSC administration is the combination of systemic and local delivery. Treatment of recipient mice with MSCs suppressed neutrophil, macrophage, and T-cell infiltration and reduced fibrosis. These beneficial effects were observed despite lack of significant MSC epithelial engraftment or new epithelial cell generation. Our study suggests that optimal combination of systemic and local delivery of MSCs may ameliorate the development of obliterative airway disease through modulation of immune response.
机译:闭塞性细支气管炎(OB)仍然是肺移植长期存活中最重要的死亡原因。使用已建立的鼠异位气管同种异体移植模型,评估了不同的骨髓源性多能基质细胞(MSCs)给药途径对OB发育的影响。将来自BALB / c小鼠的气管植入到主要组织相容性复合体(MHC-)不同的C57BL / 6小鼠的皮下组织中。在移植时,全身或局部或通过两种途径的组合施用源自骨髓的MSC。同种异体移植物在移植后的不同时间点进行移植,并评估其上皮完整性,炎性细胞浸润,纤维化和管腔闭塞。我们发现,骨髓源性MSC给药的最有效途径是全身给药和局部给药相结合。用MSC处理受体小鼠可抑制嗜中性粒细胞,巨噬细胞和T细胞浸润并减少纤维化。尽管缺乏明显的MSC上皮植入或新的上皮细胞生成,但仍观察到了这些有益效果。我们的研究表明,MSC全身和局部递送的最佳组合可通过调节免疫应答来缓解闭塞性气道疾病的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号